Published in Blood Weekly, April 14th, 2005
"Reactivation of hepatitis B virus (HBV) infection in subjects receiving cytotoxic treatment for hematological malignancies occurs in 21%-53% of chronic hepatitis B surface antigen (HBsAg) carriers and in an unknown number of HBsAg negative subjects harboring occult HBV infection. Immunotherapy with alemtuzumab, a humanized monoclonal antibody against CD52 epitopes on lymphocyte cells produces deep immunosuppression," according to researchers in Italy.
"We describe two subjects with chronic lymphocytic leukemia and occult HBV infection who developed a virological and biochemical flare...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.